Ocuphire Pharma Management
Management criteria checks 1/4
Ocuphire Pharma's CEO is George Magrath, appointed in Nov 2023, has a tenure of less than a year. total yearly compensation is $3.15M, comprised of 3% salary and 97% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth €42.95K. The average tenure of the management team and the board of directors is 0.6 years and 3.6 years respectively.
Key information
George Magrath
Chief executive officer
US$3.1m
Total compensation
| CEO salary percentage | 3.0% |
| CEO tenure | less than a year |
| CEO ownership | 0.1% |
| Management average tenure | less than a year |
| Board average tenure | 3.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$11m |
| Dec 31 2023 | US$3m | US$96k | -US$10m |
Compensation vs Market: George's total compensation ($USD3.15M) is above average for companies of similar size in the German market ($USD433.62K).
Compensation vs Earnings: Insufficient data to compare George's compensation with company performance.
CEO
George Magrath (40 yo)
less than a year
Tenure
US$3,146,518
Compensation
Mr. George Magrath, MD, MBA, Ms. serves as CEO & Director of Ocuphire Pharma, Inc. since November 1, 2023. He was an Analyst at Edison Investment Research Limited since 2015. He covered the healthcare sect...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$3.15m | 0.12% $ 43.0k | |
| Senior Vice President of Corporate Development & Secretary | no data | US$789.92k | 0.42% $ 154.3k | |
| Chief Medical Advisor & Director | no data | US$662.10k | 0.28% $ 103.5k | |
| Senior Vice President of Finance | no data | US$789.92k | 0.030% $ 11.0k | |
| Chief Financial Officer | less than a year | no data | 0.58% $ 214.8k | |
| Chief Operating Officer | less than a year | no data | 0.0077% $ 2.9k | |
| Chief Scientific & Development Officer | less than a year | no data | 0.30% $ 112.4k | |
| Head of Market Development & Commercialization | 2.4yrs | no data | no data | |
| Director & Corporate Controller | no data | no data | no data |
0.6yrs
Average Tenure
46yo
Average Age
Experienced Management: R3X1's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$3.15m | 0.12% $ 43.0k | |
| Chief Medical Advisor & Director | 3yrs | US$662.10k | 0.28% $ 103.5k | |
| Independent Director | 3.6yrs | US$154.81k | 0.35% $ 130.1k | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Independent Director | 3.6yrs | US$1.35m | 0.63% $ 233.4k | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | 4.4yrs | no data | no data | |
| Independent Director | 3.6yrs | US$135.34k | 0.38% $ 141.6k | |
| Independent Chairman | 3.6yrs | US$174.62k | 0.14% $ 51.4k | |
| Lead Independent Director | 3.6yrs | US$149.56k | 0.18% $ 67.6k | |
| Member of Medical Advisory Board | 2.5yrs | no data | no data | |
| Member of Medical Advisory Board | 2.5yrs | no data | no data |
3.6yrs
Average Tenure
58yo
Average Age
Experienced Board: R3X1's board of directors are considered experienced (3.6 years average tenure).